Bestasol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bestasol

What is Bestasol? Definition, Class, and General Purpose

Property Description
Active Ingredient Clobetasol Propionate
Pharmacological Class Topical Corticosteroid (Glucocorticoid)
Potency Super-high potency (Group I)
Primary Route Topical (Dermatologic)
Origin Synthetic
General Purpose Relieves inflammation and itching

Bestasol is a prescription-only medication whose active component is clobetasol propionate. It is classified as a topical dermatologic agent, a designation that means its use is restricted exclusively to the surface of the skin or scalp.


Identity and Pharmacological Class

Bestasol is a synthetic topical corticosteroid belonging to the high-level glucocorticoid class. The active ingredient, clobetasol propionate, is a specialized, fluorinated derivative of prednisolone that is classified as a highly potent corticosteroid. This compound is noted for its profound biological impact. Unlike low-potency products, the clobetasol propionate contained in Bestasol is designated in the super-high potency range, or Group I, which confirms its role in addressing severe inflammatory conditions that require robust therapeutic intervention.


Composition, Potency, and Available Forms

Clobetasol propionate is a single-ingredient product combined with a pharmaceutical base or vehicle for drug delivery. This synthetic substance is available in various specialized dosage forms tailored for specific skin areas, including a cream, ointment, gel, solution (often used for the scalp), foam, and shampoo. The high concentration and delivery system ensure effective penetration of the active ingredient into the skin. This range of forms enables practitioners to select the most appropriate base—such as a liquid solution versus an occlusive ointment—based on the location and characteristics of the dermatosis.


What is Bestasol Generally Used For?

The general therapeutic purpose of Bestasol is to provide powerful relief from inflammatory and pruritic manifestations in the skin. The active ingredient achieves this general benefit through its strong anti-inflammatory action and its distinct antipruritic action, which rapidly reduces persistent, intense itching. By operating as a glucocorticoid, the medication effectively helps to suppress the excessive local immune response responsible for the symptoms of various severe, corticosteroid-responsive skin conditions.

What side effects are possible with Bestasol?

Possible Side Effects and Safety Information for Bestasol (Clobetasol Propionate)

Bestasol is a highly potent topical corticosteroid. The safety profile is characterized by risks related to both local application and systemic absorption, which is augmented by use over large surface areas, prolonged duration, or under occlusive dressings.


Key Adverse Reactions and Frequencies

Classification Examples of Reactions (System-Organ Class)
Most Common (Incidence geq 1%) Burning, stinging, skin atrophy, telangiectasia, discomfort of skin, skin dryness (Skin)
Common (Incidence < 2%) Pruritus, irritation, erythema, folliculitis, fissuring of the skin, numbness of fingers (Skin)
Not Known (Postmarketing) Glaucoma, posterior subcapsular cataract (Ophthalmic)

Serious Safety Considerations and Restrictions

Systemic Effects: Due to potential systemic absorption, the drug can cause reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and Cushing's syndrome manifestations, including hyperglycemia. Periodic evaluation for HPA axis suppression is required for certain patients.

Local and Ophthalmic Risks: Serious local risks include skin atrophy and potentially irreversible effects like striae. Ophthalmic adverse reactions, such as cataracts and glaucoma, have been reported with topical use, particularly around the eyes.

Safety Limitations:

  • Total weekly dosage must not exceed 50 grams.
  • Treatment is typically limited to two consecutive weeks for most indications.
  • The drug is contraindicated for use in patients with rosacea or perioral dermatitis.
  • Use on the face, groin, or axillae (underarms) is generally restricted or not recommended.
  • Children are at a greater risk for systemic toxicity due to a higher surface area to body mass ratio.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Bestasol (clobetasol propionate) focuses primarily on the risks associated with systemic absorption following chronic overdosage or misuse, rather than acute toxicity from normal use. Overexposure to this super-high potency topical corticosteroid may lead to documented manifestations of hypercortisolism (Cushing's syndrome) and reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, according to regulatory documents.

Signs of systemic overexposure may include clinical features of hypercortisolism, as well as laboratory findings such as hyperglycemia and glucosuria (sugar in the urine). Children may be more susceptible to systemic toxicity and require careful monitoring for potential adverse outcomes like growth retardation.


Official Emergency and Management Statements

Situation Regulator-Mandated Action
Acute Ingestion (swallowing product) Seek immediate medical attention or contact a poison control center at once.
Chronic Overdose (signs of HPA suppression) Management involves gradual withdrawal of the drug under medical supervision to avoid the serious outcome of glucocorticosteroid insufficiency.

Regulatory documentation confirms that no specific antidote is known for reversing the systemic effects of clobetasol propionate. Monitoring requirements, such as periodic evaluation for HPA axis suppression, are necessary for patients at high risk of systemic exposure.

Therapeutic Uses of Bestasol

What Bestasol treats: main uses and benefits

The medication is applied across domains where additional symptomatic support is needed in situations involving certain distressing symptoms. Its active ingredient is a super-high potency topical agent relevant in contexts marked by increased discomfort or tension. It is commonly used across conditions presenting with acute episodes, including moderate to severe plaque psoriasis and forms of eczema that present with resistant manifestations.


The medication helps address symptom clusters that may become intense or disruptive, including severe itching (pruritus), pronounced redness, and noticeable skin thickening and scaling. It is relevant when supportive symptom management is appropriate for difficult-to-treat areas like the scalp or the palms and soles, where short-term assistance is needed.

"It provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms."

This focused application supports physical comfort during symptomatic phases.

Quick Fact: Relief for Resistant Symptoms
This super-high potency agent is commonly used for conditions that present with significant symptomatic burden, addressing challenging flares of inflammation and pruritus.

Eligibility and Restrictions for Use

Who Can and Cannot Use Bestasol?

Eligibility for Bestasol (clobetasol propionate) is strictly controlled by regulatory bodies due to its super-high potency. Official labeling determines who is permitted to use the medication and who is excluded.

Contraindications and Restrictions

The medicine is contraindicated in patients with a known hypersensitivity to the active ingredient or any component of the preparation. It must not be used in infants under one year of age. Use is also prohibited for treating conditions like rosacea and perioral dermatitis, and on the face, groin, or axillae (underarms).

Age Group Eligibility Regulatory Status (Official Labeling)
Infants (< 1 year) Contraindicated
Children (1 to < 12 years) Not recommended; safety and effectiveness are not established
Adolescents (12+ years) Approved for use

Conditional Use Populations

Use is conditional for certain groups:

  • Pregnancy: Classified as Pregnancy Category C; use is only permitted if the potential benefit outweighs the potential risk to the fetus.
  • Lactation: Caution is required. The product must not be applied to the breast or nipple area during breastfeeding.
  • Organ Impairment: Patients with impaired liver or kidney function require caution due to an increased risk of systemic absorption and toxicity.

What should I know about interactions with other medicines?

Official Interaction Profile


The regulatory profile for Bestasol (clobetasol propionate) is defined by officially documented patterns concerning its systemic exposure when co-administered with specific medicinal products.

Pharmacokinetic Interactions

Co-administration with certain medicinal products that are classified as strong CYP3A4 inhibitors may inhibit the metabolic clearance of the active ingredient. Specific examples of these inhibitors explicitly referenced in regulatory documents include Ritonavir and Itraconazole. This inhibition of metabolism is officially documented to result in a clinically relevant increased systemic exposure of the corticosteroid.

Additive Exposure and Restrictions

The concurrent use of Bestasol with other corticosteroid-containing products, whether administered topically or orally, carries a regulatory restriction due to the risk of an additive glucocorticoid effect. This pharmacodynamic interaction increases the total systemic exposure to the corticosteroid class. No combinations are formally listed as strictly contraindicated in the official prescribing information, and no specific timing-based separation rules for administration are documented.

Population-Specific Exposure Risks

The documented relevance of these interaction risks is elevated in specific patient populations. The official interaction profile notes that individuals with hepatic impairment may experience delayed metabolism and elimination if systemic absorption occurs. Furthermore, pediatric patients are identified as a population with increased susceptibility to the risk of systemic exposure due to physiological factors. The regulatory profile does not specify interactions with food, alcohol, or herbal products.

Mechanism of Action

Bestasol's mechanism of action is rooted in its inherent capacity to modulate cellular function at the genetic and biochemical levels, primarily through three distinct domains.


Activating the Intracellular Glucocorticoid Receptor

The drug initiates its effect by acting as an agonist for the Glucocorticoid Receptor (GR) inside cells, leading to nuclear binding and the modulation of Glucocorticoid Response Elements (GREs). This core genomic action triggers the synthesis of proteins that reduce inflammatory signaling, while simultaneously inhibiting genes that promote inflammation.


Suppressing Inflammatory Mediator Synthesis

The genetic shift causes the production of proteins, such as Lipocortin, which indirectly inhibit the enzyme Phospholipase A2 (PLA2). This inhibition of PLA2 limits the release of arachidonic acid, thereby preventing the biosynthesis of pro-inflammatory molecules like prostaglandins and leukotrienes at an early, decisive stage in the cascade.


Local Vasoconstriction and Immune Cell Regulation

Clobetasol Propionate exerts a direct effect on the local circulatory system, causing vasoconstriction that reduces blood flow and fluid leakage, resulting in the physiological reduction of local tissue edema and erythema. Simultaneously, it suppresses the function and migration of immune cells by inhibiting key transcription factors like NF-kappaB, leading to reduced cellular activity at the site of application.

Dosage and Administration Information

Administration Instructions for Bestasol

Bestasol is a highly potent corticosteroid formulated for topical use only and must be applied strictly according to guidelines to minimize systemic absorption. It is not for ophthalmic, oral, or intravaginal use.

Administration Scope Standard Protocol
Route of Administration Topical use (on the skin) only.
Dosing Schedule Apply a thin uniform film to the affected skin twice daily.
Dose Limitation The total dosage must not exceed 50 grams per week.
Treatment Duration Treatment beyond two consecutive weeks is not recommended. Discontinue when control of the condition is achieved.
Age Group Rule Use is not recommended in children under 12 years of age.

Procedural Steps (for Foam/Aerosol preparations)

  1. Shake the can well before each use.
  2. Turn the can completely upside down and depress the actuator to dispense a small amount into the palm of the hand.
  3. Apply a thin layer to the affected area(s) and rub in gently until the foam disappears.
  4. Wash hands thoroughly after applying the product, unless the treatment area is the hands themselves.

Special Administration Conditions

  • Avoid use on the face, groin, or axillae (underarms).
  • Avoid contact with eyes.
  • Do not use the product with occlusive dressings (e.g., bandages or wraps) unless specifically directed by a qualified physician.

Following these precise application and duration limits is established for the short-term use of Bestasol and serves as the procedural structure for its administration.

Recent Clinical Evidence

Recent Clinical Evidence

Overview of Studies

Bestasol (clobetasol propionate) is a very high-potency topical corticosteroid, and research focuses on its use in managing severe, inflammatory skin conditions such as moderate to severe plaque psoriasis and other corticosteroid-responsive dermatoses. Clinical trials and systematic reviews typically evaluate the drug's short-term efficacy and safety profile against a placebo or lower-potency treatments.

Efficacy Findings

Controlled clinical trials, including randomized, double-blind studies, have investigated the use of Bestasol for a limited duration, typically two to four weeks. These studies generally found that a greater percentage of patients treated with Bestasol achieved clinical resolution or a significant improvement in symptoms (e.g., reduction in scaling, redness, and plaque elevation) compared to a non-active vehicle (placebo).

Key measures used in these studies include the Physician's Global Assessment (PGA) or similar scales, which assess the overall severity of the condition.

Safety and Tolerability Data

Safety evaluations in clinical trials focus on local adverse events at the application site and the potential for systemic effects. The most common adverse events documented in studies have included burning and stinging sensations, irritation, and pruritus (itching).

Because of its high potency, one critical area of study involves the risk of Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, which is a possible systemic effect. Studies confirm that this risk exists and generally support that the drug is to be used for the minimum time necessary to achieve desired results. Long-term safety data is primarily derived from post-marketing surveillance.

Frequently Asked Questions (FAQ)

Common questions about Bestasol (FAQ)

Q: Do many people experience weight gain while using Bestasol?

A: The official product information does not list weight gain as a common side effect reported in clinical trials. However, rapid weight gain and facial swelling can be signs of a rare, more serious systemic effect known as Cushing's syndrome. This condition is described in regulatory documents as a potential risk with high-potency topical corticosteroids due to the possibility of systemic absorption.

Q: Is dizziness a common side effect of Bestasol?

A: Dizziness is not categorized as a common local adverse reaction for this topical medication. Official safety information, however, cites feeling dizzy or faint as possible symptoms of serious systemic effects, such as high blood sugar or adrenal gland issues. These types of effects are associated with systemic absorption, which is a risk noted when the medication is used over large areas or for extended periods.

Q: Can Bestasol cause sleepiness or affect my alertness?

A: Feeling sleepy or drowsy is not a typical side effect of this topical medicine. Nevertheless, regulatory patient information lists changes in mental state, such as feeling sleepy or confused, as signs that might indicate a potential serious systemic issue related to the adrenal glands.

Q: Is Bestasol known to interact with alcohol?

A: According to the official regulatory interaction profile, there is no specific interaction listed between the active ingredient in Bestasol and alcohol. The official documents also do not specify interactions with food or herbal products.

Q: Is it safe to take Bestasol if I am already taking blood pressure medication?

A: Official safety information notes that topical corticosteroids carry a documented risk of systemic absorption, which can lead to effects like high blood pressure (hypertension). The potential for systemic effects is a consideration often noted by prescribers when reviewing other medications being taken.

Q: What happens if I miss a dose of Bestasol?

A: Regulatory patient instructions address what to do if a dose is missed. If remembered soon after the scheduled time, the dose should be applied. However, if it is almost time for the next application, it is recommended to skip the missed dose and resume the normal dosing schedule. Official instructions advise that double applications should be avoided.

Q: What should I do if I accidentally take two doses of Bestasol?

A: Bestasol is a potent medication with a strict weekly dosage limit established in official documents. Exceeding the amount prescribed, even accidentally, increases the risk of systemic absorption. Systemic absorption is a possibility that is associated with serious side effects, such as HPA axis suppression.

Q: What are the rules regarding Bestasol and breastfeeding?

A: Official regulatory documents advise caution regarding use during breastfeeding. It is recommended to use the smallest amount of medication on the smallest area of skin for the shortest possible duration. Furthermore, the product must not be applied directly to the breast or nipple area.

Q: What is the difference between Bestasol and a supplement I see advertised?

A: Bestasol is a prescription-only medication that contains a synthetic, super-high potency corticosteroid. This pharmacological classification means it is strictly regulated as a drug by governmental bodies. Supplements, by contrast, are regulated differently and are not intended to treat, diagnose, or cure disease.

Q: Is Bestasol known to affect blood sugar levels?

A: Due to the potential for systemic absorption of the active ingredient, Bestasol can cause effects on the endocrine system. Official documents note that this may include hyperglycemia, which is high blood sugar. This is a potential risk noted in official documents. Depending on the patient's individual circumstances, periodic evaluation may be required.

Q: Is Bestasol a controlled substance or just a prescription drug?

A: Bestasol is classified as a prescription-only medication. Official documents confirm that it is not scheduled under the DEA Controlled Substances Act, meaning it is not considered a controlled substance.

Q: Why is Bestasol available only with a prescription?

A: The medication is restricted to prescription use because it is classified as a super-high potency topical corticosteroid. This potency carries the potential risk of causing serious systemic effects, such as the suppression of the Hypothalamic-Pituitary-Adrenal (HPA) axis, if not used under medical supervision.

Q: Is Bestasol considered a fast-acting medication?

A: While the term 'fast-acting' is not used in the official label, the therapeutic purpose is described as providing powerful and rapid relief from severe inflammation and itching. Regulatory instructions strictly limit the treatment duration, typically to two consecutive weeks, emphasizing its use as a potent, short-term treatment.

Q: What happens if I stop taking Bestasol suddenly?

A: Official patient information advises that for long-term or prolonged use, the medicine may need to be gradually reduced before stopping. Abruptly discontinuing the medication increases the potential for rebound symptoms or withdrawal reactions due to the risk of HPA axis suppression.

Q: Has there been a recall or safety alert issued for Bestasol recently?

A: Regulatory bodies have previously issued recalls for certain batches of generic clobetasol propionate ointment. These recalls were sometimes due to issues like microbial contamination found in specific lot numbers. Official regulatory bodies are the source for the most current information regarding safety alerts or recalls.

Q: Why do some people say they felt worse when they first started Bestasol?

A: The most commonly documented adverse events occur at the application site and include sensations of burning, stinging, discomfort, and irritation. These are generally temporary local side effects that a patient may notice immediately when the product is first applied.

Q: Is it necessary to have blood tests while on Bestasol?

A: Official labeling states that periodic evaluation for Hypothalamic-Pituitary-Adrenal (HPA) axis suppression may be required for certain patients who are using the medication for extended periods. This evaluation is often performed using the ACTH stimulation test, which is a procedure involving the collection of blood samples.

Q: Can Bestasol be crushed or chewed if someone has trouble swallowing pills?

A: Bestasol is a topical medication formulated to be applied exclusively to the skin or scalp, depending on the dosage form. It is not an oral medication and should never be swallowed or taken by mouth.

Q: Is there a generic version of Bestasol available?

A: Yes, the active ingredient in Bestasol, Clobetasol Propionate, is widely available in the marketplace. Regulatory documentation confirms that this active ingredient is marketed under numerous generic drug applications.

Q: Why do some people feel nausea when first taking this drug?

A: Nausea and vomiting are not listed as common adverse effects. However, feeling sick is cited in regulatory patient safety warnings as a possible symptom of potential serious systemic effects, such as issues with the adrenal glands.

Q: Is Bestasol habit-forming or addictive?

A: The official labeling does not classify the medication as habit-forming or addictive. The documented risk is physiological and relates to the Hypothalamic-Pituitary-Adrenal (HPA) axis suppression. This means prolonged use may require the medication to be gradually stopped to prevent potential rebound symptoms.

Q: Is it true that Bestasol might cause skin reactions?

A: Yes, the regulatory label lists many local adverse reactions at the site of application. These include common sensations like burning and stinging, as well as skin changes such as skin atrophy and irritation.

Q: Is there any evidence about Bestasol affecting fertility in men or women?

A: Official regulatory review documents contain non-clinical data from animal studies that examined the effect of the active ingredient on fertility and general reproductive toxicity in rats. This information is considered when assessing the overall safety profile of the medication.

Q: Can Bestasol be taken on an empty stomach?

A: Bestasol is a topical medication that is applied directly to the skin or scalp and is not swallowed. Since it is not an oral drug, instructions regarding taking it on an empty or full stomach do not apply to this product.

How should Bestasol be stored and disposed of?

How to Store and Dispose of Bestasol (Clobetasol Propionate)

Bestasol must be stored strictly according to regulatory requirements to maintain its stability. All formulations require storage at controlled room temperature, typically between 15 C to 30 C (59 F to 86 F). The product must not be refrigerated or frozen.

All Bestasol products must be stored out of the sight and reach of children.

Special Handling and Disposal

Certain pressurized formulations, such as the foam and spray, are labeled as flammable and must be kept away from heat or open flame. The pressurized can must not be punctured and must never be thrown into a fire, even if empty. Storage temperatures for the foam must not exceed 120 F (49 C).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bestasol found in:

A-Z Index: